Moderna may expand pediatric COVID-19 vaccine trial
The drug maker plans to expand the size of its trial to look for "rarer events" of side effects.
Alexander Tin is a digital reporter for CBS News based in the Washington, D.C. bureau. He covers the Biden administration's public health agencies, including the federal response to infectious disease outbreaks like COVID-19. Previously, he was a campaign reporter for CBS News based out of Las Vegas, where he was raised. He covered presidential, Senate and House candidates for the 2020 election cycle in Arizona, California, Nevada and New Mexico. He has also worked in Washington for "Face the Nation" and in New York for the "CBS Evening News." Tin graduated from Columbia University in 2017 with a bachelor's degree in political science.
The drug maker plans to expand the size of its trial to look for "rarer events" of side effects.
As early as this fall, U.S. regulators could decide whether some people should get booster shots.
The decision comes after federal health officials identified a very rare pattern of the potentially serious nervous system disorder in some recipients of the vaccine.
The U.S. is currently averaging less than 300,000 first doses daily, according to figures published by the CDC.
The Centers for Disease Control and Prevention said this would be its "final extension."
The nationwide death rate has slowed to a level not seen since the early weeks of the pandemic – but unvaccinated people are still at risk as more contagious variants spread.
The raging pandemic continues to claim millions of lives around the world, even as vaccinations have curtailed the worst of the virus's spread in the U.S.
Reported cases represent just a tiny fraction of the nearly 130 million Americans who have been fully vaccinated with either Pfizer or Moderna's doses.
They'll be distributed this year and next and will be given to 92 nations.
The milestone comes as the nationwide pace of vaccinations has slowly picked up.
Most Americans will not be able to get a "vaccine passport" soon.
Many adolescents could get their first doses within the coming days.
The next generation of COVID vaccines may come in different forms and might even help prevent future pandemics.
A federal official confirmed the FDA is expected to authorize Pfizer's COVID-19 vaccine for children as young as 12 years of age.
As demand slows, health officials shift from triaging a flood of people clamoring for the shots to targeting harder-to-reach communities.